Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using MDGN201 TARGTEPO
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2018
Price : $35 *
At a glance
- Drugs MDGN 201 (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors Aevi Genomic Medicine
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 09 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
- 09 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Mar 2017.